Lv1
60 积分 2023-11-24 加入
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
2天前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
4天前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
12天前
已完结
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
4个月前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
5个月前
已完结
Neoadjuvant and Adjuvant Therapy Approaches to Gastric Cancer
7个月前
已完结
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
7个月前
已完结
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
10个月前
已完结
Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression
10个月前
已完结
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
11个月前
已完结
皖公网安备34019202002308
